Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CDC25B | P30305 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5551252 | 0.92 | ALDH1A1 (0.43) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL17949283 | 0.84 | SMN1; SMN2 (0.46) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL8082401 | 0.80 | SMN1; SMN2 (0.44) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL15368459 | 0.80 | PER2 (0.45) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL4985094 | 0.79 | CASP3 (0.46) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL8082397 | 0.79 | SMN1; SMN2 (0.43) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL8082404 | 0.79 | SMN1; SMN2 (0.43) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL4985086 | 0.79 | CASP3 (0.46) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL5038822 | 0.78 | GLA (0.42) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL10795974 | 0.78 | CASP3 (0.46) | ALDH1A1MAPK1L3MBTL1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1301750-C | Conjugates of macrocyclic metal complexes with biomolucules and utilization thereof for producing agents for use in NMR diagnosis and radiodiagnosis and radiotherapy | SCHERING AG (DE) | 2007-02-28 | — | — | CN | disclosed |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2007-01-18 | — | — | US | disclosed |
| US-7164016-B2 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-16 | — | — | US | disclosed |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2007-01-11 | — | — | US | disclosed |
| CN-1541114-A | Conjugates of macrocyclic metal complexes with biomolucules and utilization thereof for producing agents for use in NMR diagnosis and radiodiagnosis and radiotherapy | ���ֹɷݹ�˾ | 2004-10-27 | — | — | CN | disclosed |
| CN-1533286-A | Macrocyclic metal complexes and use thereof for production of conjugates with biomolecules | ���ֹɷݹ�˾ | 2004-09-29 | — | — | CN | disclosed |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | SCHERING AG (DE) | 2003-11-06 | — | — | US | disclosed |
| US-20030108486-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | SCHERING AG (DE) | 2003-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108486-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | ALDH1A1 3392/4885MAPK1 3917/4885L3MBTL1 3120/4885 |
| US-20070014725-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | ALDH1A1 2758/4885MAPK1 3745/4885L3MBTL1 3119/4885 |
| US-20030206865-A1 | Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for NMR diagnosis and radiodiagnosis as well as radiotherapy | CA13, CA14, CA12 | ALDH1A1 2758/4885MAPK1 3745/4885L3MBTL1 3119/4885 |
| US-20070009442-A1 | Macrocyclic metal complexes and their use for the production of conjugates with biomolecules | CA13, MPI, CA14 | ALDH1A1 3392/4885MAPK1 3917/4885L3MBTL1 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.